Kiefel’s new machine is designed to form, fill, and seal up to 6,000 infusion, parenteral nutrition, or dialysis bags per hour.
Broader industry shifts may lead outsourcing companies to prioritize integrated services.
Context surrounding the Inflation Reduction Act is necessary for a comprehensive understanding of the global biopharma market.
Biogen’s acquisition of Reata will grant them access to Reata’s FDA-approved treatment for Friedreich’s ataxia.
AstraZeneca, via its subsidiary Alexion Pharmaceuticals, will purchase a portfolio of preclinical rare disease gene therapies from Pfizer in a deal worth up to $1 billion.
Roche will pay up to $2.8 billion for the rights to Alnylam’s RNA-based hypertension therapeutic.
The partnership will see Flagship and Pfizer work to create a new pipeline of innovative medicines.
The expanded deal, now potentially worth more than $1.2 billion, will work to develop in vivo therapies, including sickle cell disease.
Westlake’s third fund of $450 million will be used to grow early stage biotechnology companies.
Eisai’s lecanemab-irmb was converted from an accelerated approval to a traditional approval.